Simethicone solid oral dosage form
View Patent ↗The present invention provides a composition for forming a compressed solid dosage form that is a free-flowing compressible admixture of simethicone, an adsorbant, and an optional active agent, wherein the weight ratio of simethicone to adsorbent is at least 1:2.22. Also included are solid dosage forms made from a free-flowing compressible admixture of simethicone, an adsorbant, and an optional active agent, wherein the weight ratio of simethicone to adsorbent is at least 1:2.22.
1. A composition for forming a compressed solid dosage form comprising a free-flowing compressible admixture of simethicone and an adsorbent comprising silicified microcrystalline cellulose and magnesium aluminometasilicate, wherein the weight ratio of simethicone to adsorbent is at least about 1:1.75, and wherein the composition has at least 30 wt % simethicone.
2. A composition of claim 1 , further comprising at least one additional active agent.
3. A composition of claim 2 , wherein the active agent is selected from the group consisting of a bisacodyl, a famotidine, a prucalopride, a diphenoxylate, a loperamide, a lactase, a mesalamine, a bismuth, and pharmaceutically acceptable salts and mixtures thereof.
4. A composition of claim 3 , wherein the active agent is loperamide, or pharmaceutically acceptable salts thereof.
5. A composition of claim 1 , having from 31 wt % to 35 wt % simethicone.
6. A composition of claim 1 , having from about 19 wt % to about 27 wt % silicified microcrystalline cellulose and having from about 31 wt % to about 39 wt % magnesium aluminometasilicate.
7. A composition of claim 6 , having from about 23 wt % to about 27 wt % silicified microcrystalline cellulose and from about 33 wt % to about 37 wt % magnesium aluminometasilicate.
8. A composition of claim 1 , wherein the composition is compressed into a tablet having a hardness value of at least 2 kp/cm 2 .
9. A composition of claim 8 , wherein the composition is compressed into a tablet having a hardness value of from about 5 to about 10 kp/cm 2 .
10. A solid oral dosage form comprising a compressed admixture of simethicone, silicified microcrystalline cellulose, and magnesium aluminometasilicate, wherein the simethicone is adsorbed on the silicified microcrystalline cellulose and magnesium aluminometasilicate, wherein the weight ratio of simethicone to the silicified microcrystalline cellulose and magnesium aluminometasilicate adsorbent is at least about 1:1.75, and wherein the composition has at least 30 wt % simethicone.
11. A solid oral dosage form of claim 10 , further comprising at least one additional active agent.
12. A solid oral dosage form of claim 11 , wherein the active agent is selected from the group consisting of a bisacodyl, a famotidine, a prucalopride, a diphenoxylate, a loperamide, a lactase, a mesalamine, a bismuth, and pharmaceutically acceptable salts and mixtures thereof.
13. A solid oral dosage form of claim 12 , wherein the active agent is loperamide, or pharmaceutically acceptable salts thereof.
14. A solid oral dosage form of claim 10 , having from 31 wt % to 35 wt % simethicone.
15. A solid oral dosage form of claim 10 , having from about 19 wt % to about 27 wt % silicified microcrystalline cellulose and having from about 31 wt % to about 39 wt % magnesium aluminometasilicate.
16. A solid oral dosage form of claim 15 , having from about 23 wt % to about 27 wt % silicified microcrystalline cellulose and from about 33 wt % to about 37 wt % magnesium aluminometasilicate.
17. A solid oral dosage form of claim 10 , wherein the composition is compressed into a tablet having a hardness value of at least 2 kp/cm 2 .
18. A solid oral dosage form of claim 10 , wherein the composition is compressed into a tablet having a hardness value of from about 5 to about 10 kp/cm 2 .
19. A composition of claim 3 , wherein the active agent is bisacodyl, or pharmaceutically acceptable salts thereof.
20. A composition of claim 2 , wherein the active agent is selected from the group consisting of acetaminophen, ibuprofen, naproxen, ketoprofen, cyclobenzaprine, meloxicam, rofecoxib, celecoxib, and pharmaceutically acceptable salts and mixtures thereof.